Skip to content
Austin Top 50
Author:
Classover Holdings Inc.
KIDZ AI Announces Expansion of Existing Share Repurchase Program by 50% to $3.0 Million
July 28, 2026
KIDZ AI Issues Shareholder Letter Addressing Disconnect Between Current Share Price and Fundamentals
July 27, 2026
Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
July 23, 2026
KIDZ AI Enters into $44.6 Million Definitive GPU Compute Services Agreement with Canopy Wave
July 21, 2026
KIDZ AI Wins 2026 EdTechX Award and Unveils KIDZBot AI Robotics Platform
July 6, 2026
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
June 25, 2026
Zepbound (tirzepatide) and Shaquille O’Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
June 10, 2026
KIDZ AI Named Finalist at the 2026 EdTechX Awards as Company Advances AI-Native Education Operating System, Agent Workflows and Robotics Learning Platform
June 10, 2026
Lilly’s oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
June 9, 2026
Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
June 8, 2026
1
2
3
…
5
Next Page
→